, which have been captured using AA or GG adaptors. The DNA sequences of PCR primers (red), genomic locus (purple), targeted dinucleotides (blue), AcuI motif (green) and adaptors (brown) are
shown.
(C) PCR amplification (18 cycles) of captured AcuI-digested DNA products by DTECT using specific (green) and non-specific (blue) DNA adaptors. Each of the 16 adaptors was tested for its ability to capture two independent dinucleotide signatures (#1 and #2).
Figure S3
A Figure 2G -I. Cells were transfected with the cytidine base editor (CBE) BE3 and an sgRNA to induce a STOP codon (sgSTOP) using iSTOP. WT and STOP alleles were then cloned and mixed at different WT:STOP ratios, as indicated in Figure 2G . DTECT was then used to capture WT and STOP signatures using adaptors specific for the WT (green) or STOP (purple) allele, as well as non-specific adaptors (blue). Captured material was then subjected to analytical or quantitative PCR.
(B) Sanger sequencing reads of WT and STOP alleles of SPRTN, SMARCAL1 and PIK3R1. The targeted dinucleotide signature is shown in green and the edited cytidine base (C-> T) is indicated by the blue arrow.
(C) Representation of the AcuI-tagging primers used to detect the WT and STOP alleles of the SPRTN gene. The targeted dinucleotides are shown in blue, the edited base is indicated with an asterisk, the PAM sequence is show in red and part of the AcuI-tagging primer sequence is shown in purple.
(D) PCR amplification (25 cycles) of WT and STOP SPRTN alleles (arrow) captured using DTECT from WT:STOP allele mixtures (i.e., 100:0 and 99:1). An adaptor (AG) specific for the STOP SPRTN allele is utilized in the capture reaction, along with an adaptor specific for the WT allele (GG; positive control) and a non-specific adaptor (TT; negative control). Background non-specific PCR products are indicated with an asterisk.
(E) Frequency of non-specific dinucleotide capture for each of the 16 adaptors used for DTECT. Adaptors containing the indicated dinucleotide sequences were utilized to capture AcuI-digested DNA fragments with non-complementary dinucleotides and the frequency of non-specific dinucleotide capture was quantified by qPCR. Mean frequency of non-specific dinucleotide capture is shown for 2-6 independent DNA ligation reactions using DNA fragments with distinct non-complementary dinucleotides. Adaptors complementary to +1 and -1 AcuI-dependent slippage events were excluded from the analysis. Technical duplicates of DTECT assays correspond to two independent ligation reactions for the same AcuI-digested amplicon and Sanger-based technical duplicates correspond to two independent sequencing reactions for the same PCR amplicon. shown in Figure 5I .
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D Figure S8 Mouse #2 #1 #4 #3 #2 #1 #4 #3 #2 #1 #4 #3 #2 #1 #4 #3
Signature #1
Signature #2 Signature #3 Signature #4
Jak2 WT Jak2 V617F
Mouse #1 G T C G->T G G T T G T G T C T G T G G
Mouse #3
Mouse #2
Mouse #4 (D) Analytical detection of the indicated NT5C2 mutations in ALL patient samples by PCR (20 cycles). The frequency of the indicated mutations in the same patient samples is shown in Figure 6B . (80,326; blue) or without (345,254; green) genomic AcuI sites in close proximity (+/-100 bp). Variants (green, right pie chart) with a single AcuI motif located 35 bp to 100 bp away on the 3'-(29,848) or 5'-(29,291) side can be detected using DTECT, as illustrated in (C).
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Variants (red, right pie chart) with an AcuI motif located <35 bp away (18, 739) or with proximal AcuI motifs on both sides (2,448) cannot be detected using DTECT.
(B) Percentage and number of ClinVar variants that can (95.02%, 404,393) or cannot (4.98%, 21,187) be detected using DTECT.
(C) Schematic representation of genomic loci with or without an AcuI site in close proximity to the edited site. When a genomic AcuI site is located 35 bp to 100 bp away from the edited site, detection of the edited site can be obtained by designing 2 AcuI-tagging primers that anneal to the targeted locus between the genomic AcuI site and the edited base(s). This approach allows the capture of two independent dinucleotide signatures for each targeted site with one proximal AcuI site. Four independent dinucleotide signatures can be captured for targeted sites with no proximal AcuI sites. The dinucleotide signatures captured to detect the TP53 R209fs*6 and PAM mutations are shown in purple. The presence of indel interference in the distinct predicted alleles is indicated. MH, microhomology.
Figure S10
(B) DTECT-based quantification of the TP53 R209fs*6 and PAM mutations introduced by HDR using a single ssODN donor template, as shown in (A). Adaptors specific for the WT (CT and TG; green and red) or edited (TT; purple) signatures were used for quantification. HDR efficiency determined by NGS is also shown.
(C) Schematic representation of the design of DTECT experiments to avoid interference of indels formed at DSBs during CRISPR-mediated HDR. Cas9-mediated DSBs are induced at a distance from a targeted dinucleotide (green) sufficient to avoid mutation of the targeted dinucleotide by indels (blue). The pattern of indel mutations is predicted using the InDelphi website.
(D) Schematics of alleles generated by CRISPR-mediated HDR, including the unedited allele (green), indelcontaining alleles (blue) and the HDR-edited allele (purple). Using the experimental design shown in (C), DTECT captures both the unedited and the indel-containing alleles using an adaptor specific for the WT dinucleotide signature, while the HDR-edited allele is captured using an adaptor specific for the edited dinucleotide signature. The capture of indel-containing alleles with a WT adaptor ensures the accurate quantification of the frequency of the HDR-edited allele in the allele population.
